{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n Interferon‐induced transmembrane protein 10 (IFITM10) is emerging as a less‐characterized member of the IFITM family with potential roles extending beyond classical antiviral defense. Recent studies have revealed a multifaceted profile for IFITM10. In gastric cancer, for instance, IFITM10 is highly expressed in tumor tissues—especially in early T stages—and its elevated expression correlates with favorable diagnostic performance, suggesting that it may serve as an early biomarker for disease detection."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": " In the context of viral infections, transcriptome analysis in COVID-19 retest‐positive patients demonstrated that diminished IFITM10 expression is associated with reduced activation of immune cells (e.g., lower granzyme B production), which may contribute to impaired antiviral responses."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": " Tissue expression profiling further indicates that IFITM10 exhibits a distinct pattern, with relatively higher expression levels in smooth muscle, the esophagus, and the trachea—suggesting tissue-specific roles that could relate to local antiviral defense or other physiological functions."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "3"}]}, {"type": "t", "text": " Additionally, the discovery of an in-frame CTSD-IFITM10 read-through fusion transcript in breast cancer—whose targeted silencing reduces cancer cell proliferation—points to a potential oncogenic role or, at least, a contribution to tumor cell biology, marking the fusion event as a candidate for further exploration as a therapeutic target or diagnostic marker."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "4"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n Collectively, these findings highlight the emerging and multifaceted roles of IFITM10 in both innate immunity and cancer. Although its precise mechanisms remain to be fully elucidated, the differential regulation of IFITM10 in distinct pathological contexts underlines its potential clinical significance as a biomarker and as a modulator of cell proliferation and immune activation.\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Yuanda Liu, Jingjing Liu, Zhenwei Tian, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Highly expressed IFITM10 is associated with early diagnosis and T stage of gastric cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Transl Cancer Res (2021)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.21037/tcr-20-2333"}], "href": "https://doi.org/10.21037/tcr-20-2333"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "35116268"}], "href": "https://pubmed.ncbi.nlm.nih.gov/35116268"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Dongyao Wang, Dong Wang, Min Huang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Transcriptomic characteristics and impaired immune function of patients who retest positive for SARS-CoV-2 RNA."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Mol Cell Biol (2021)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/jmcb/mjab067"}], "href": "https://doi.org/10.1093/jmcb/mjab067"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "34687295"}], "href": "https://pubmed.ncbi.nlm.nih.gov/34687295"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Yanqin Lu, Qingli Zuo, Yao Zhang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "The expression profile of IFITM family gene in rats."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Intractable Rare Dis Res (2017)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.5582/irdr.2017.01066"}], "href": "https://doi.org/10.5582/irdr.2017.01066"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "29259856"}], "href": "https://pubmed.ncbi.nlm.nih.gov/29259856"}]}, {"type": "r", "ref": 4, "children": [{"type": "t", "text": "Katherine E Varley, Jason Gertz, Brian S Roberts, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Recurrent read-through fusion transcripts in breast cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Breast Cancer Res Treat (2014)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s10549-014-3019-2"}], "href": "https://doi.org/10.1007/s10549-014-3019-2"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "24929677"}], "href": "https://pubmed.ncbi.nlm.nih.gov/24929677"}]}]}]}